IP Group Plc

Equities

IPO

GB00B128J450

Investment Management & Fund Operators

Market Closed - London S.E. Other stock markets 11:35:21 2024-04-26 am EDT			5-day change	1st Jan Change
48.85 ^GBX	+3.39%		+5.28%	-15.92%

Apr. 23	Alphawave confident in long term growth potential as revenue rises	AN
Apr. 16	Alphawave shares plunge as set to miss annual sales guidance	AN

IP Group investee pens deal with Jazz Pharmaceuticals

November 14, 2023 at 05:56 am EST

IP Group PLC - Oxford, England-based intellectual property commercialisation - Says portfolio company Autifony Therapeutics Ltd has signed a deal with Jazz Pharmaceuticals PLC worth up to USD770 million for drug discovery and preclinical development on two ion channel targets associated with neurological disorders. Jazz will lead clinical development, manufacturing and regulatory activities and commercialisation once preclinical development is finalised. IP Group holds a 26% stake in Autifony, valued at GBP4.6 million.

Current stock price: 46.55 pence, up 1.9%

12-month change: down 38%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	JAZZ PHARMACEUTICALS PLC	109.5 USD	+1.89%	-0.44%	6.82B
	IP GROUP PLC	48.85 GBX	+3.39%	+5.28%	628M

Latest news about IP Group Plc

Alphawave confident in long term growth potential as revenue rises	Apr. 23	AN
Alphawave shares plunge as set to miss annual sales guidance	Apr. 16	AN
Frontier IP hires former Argentex CFO Jo Stent as new finance chief	Apr. 12	AN
EARNINGS AND TRADING: Castillo losses double; GCP proposes wind-down	Mar. 14	AN
Mission Therapeutics Ltd. announced that it has received £25.2 million in funding from Pfizer Venture Investments LLC, Sofinnova Partners SAS, Roche Venture Fund, SR One Capital Management, LP, IP Group Plc, Rosetta Capital Limited	Mar. 13	CI
IP Group net asset value declines amid supply chain issues, inflation	Mar. 13	AN
JPMorgan raises Flutter and cuts Entain	Mar. 13	AN
IP Group Plc Do Not Propose A Full Year Dividend for 2023	Mar. 13	CI
Transcript : IP Group Plc, Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
IP Group's FY23 Loss Narrows	Mar. 13	MT
Earnings Flash (IPO.L) IP GROUP Reports FY23 Loss GBX-16.53	Mar. 13	MT
Tranche Update on IP Group Plc's Equity Buyback Plan announced on December 19, 2023.	Mar. 13	CI
IP Group Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
EARNINGS AND TRADING: Frontier IP sells last of Exscientia holding	Feb. 29	AN
IP Group expects net assets to fall in 2023 trading update	Jan. 30	AN
Enterprise Therapeutics Ltd announced that it has received £26 million in funding from Versant Venture Management, LLC, Novartis Venture Funds, Forbion Capital Partners B.V., Epidarex Capital, IP Group Plc, Panakès Partners SGR SpA	Jan. 29	CI
Frontier IP portfolio Alusid gets GBP500,000 investment from Octopus	Jan. 22	AN
Alphawave posts strong fourth quarter; maintains annual guidance	Jan. 22	AN
UBS raises GSK and cuts AstraZeneca	Jan. 16	AN
IP Group takes part in portfolio company's funding round	Dec. 22	AN
IP Group Plc commences an Equity Buyback Plan for 103,677,065 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.	Dec. 19	CI
FTSE 100 outperforms European peers	Dec. 18	AN
One Media IP expects higher revenue despite redirection of cash	Dec. 18	AN
IP Group sets GBP20 million share buyback to cut cash pile	Dec. 18	AN
IP Group Initiates GBP20 Million Buyback	Dec. 18	MT

Chart IP Group Plc

Duration

Period

More charts

Company Profile

IP Group plc is a United Kingdom-based early-stage science investor. The Company develops and supports various businesses in deep technology (deeptech), life sciences and clean technology (cleantech). Its segments include venture capital investing: life sciences, venture capital investing: deeptech, venture capital investing: cleantech, venture capital investing: other, and third-party fund management. Its life sciences investments are focused on a healthier future with a view to curing and preventing disease rather than simply treating symptoms and building healthier - rather than just longer - lives. Its deeptech investments are focused on four technology subsectors underpinned by global societal need and macroeconomic trends. Its cleantech platform, Kiko Ventures, is investing in assets that address the global climate challenge, targeting innovators that are creating scalable climate technology solutions. Its subsidiaries include Parkwalk Advisors Limited and IP2IPO Limited.

Sector

Investment Management & Fund Operators

Calendar

2024-06-12 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for IP Group Plc

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4885 GBP

Average target price

1.28 GBP

Spread / Average Target

+162.03%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Investment Management & Fund Operators

	1st Jan change	Capi.
IP GROUP PLC	-15.92%	628M
BLACKROCK, INC.	-6.03%	113B
UBS GROUP AG	-3.98%	87.91B
APOLLO GLOBAL MANAGEMENT, INC.	+20.42%	63.85B
BROOKFIELD CORPORATION	+5.29%	61.9B
BANK OF NEW YORK MELLON CORPORATION (THE)	+10.12%	42.86B
AMERIPRISE FINANCIAL, INC.	+7.95%	40.84B
3I GROUP PLC	+18.92%	34.58B
T. ROWE PRICE GROUP INC.	+5.88%	25.46B
STATE STREET CORPORATION	-5.25%	22.13B

Other Investment Management & Fund Operators